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before becoming routine care. Abstract  
 
Background:  
Early diagnosis of malignant axillary nodes in breast cancer guides the extent of 
axillary surgery: patients with known axillary malignancy receive a more extensive 
single operation at the same time as surgery to their breast. A multicentre 
randomised controlled trial assessed whether a Computed Tomography (CT) scan of 
the axilla could more accurately diagnose malignant axillary lymph node involvement 
in patients with newly diagnosed breast cancer when compared to usual care.  
 
Methods:  
Patients with newly diagnosed breast cancer (identified via screening and 
symptomatic pathways) at two NHS Trusts in the North East of England were 
recruited and randomised in equal numbers. Both groups received routine diagnostic 
and surgical care. In addition, one group received a CT scan of their axilla on the 
same side as the breast cancer.  The primary endpoint was the need to undergo a 
second axillary surgical procedure. 
 
Findings: 
The trial recruited 297 patients of whom 291 contributed to findings. The proportion of 
patients undergoing a second operation was similar (CT vs UC: 19.4% vs. 19.7%; 
CT-UC: -0.3%, 95%CI: = -9.5% to 8.9%, c2 [1]: p=1.00).  Patients in the two groups 
were similar before treatment, had similar types and grade of cancer, experienced 
similar patterns of post-operative complications and reported similar experiences of 
care. 
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Interpretation: 
CT scan-guided care did not result in a change in the number of patients requiring a 
second operation; similar numbers of patients needed further axillary surgery in both 
groups. New diagnostic imaging technologies regularly enter NHS centres. It is 
important these are evaluated rigorously 
 
Funding: 
The National Institute for Health Research’s Research for Patient Benefit Programme 
 
 
Introduction 
Breast cancer is the most common cancer in the UK despite the fact that it is rare in 
men. In 2013, there were 44,831 new cases of breast cancer diagnosed in the UK; 
comprising 44,540 (> 99%) cases in women and 291 (< 1%) cases in men.1  In 
England, data from 2004-2006 indicated that 83% of patients presenting with breast 
cancer had breast and axillary surgery or a major resection.2 
 
Accurate pre-operative axillary staging is essential in planning the management of 
patients with newly diagnosed breast cancer to inform the most appropriate axillary 
operation. 
 
Techniques of assessing axillary nodal status vary considerably between centres in 
the UK. Generally, ultrasound is used with or without fine needle aspiration cytology 
and core biopsy as a first line investigation. Whilst ultrasound-based techniques of 
staging are the most commonly used, other investigations to visualise and stage 
axillary nodal tissue in patients presenting with breast cancer are rarely used but 
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include magnetic resonance imaging (MRI)3 and Positron emission tomography 
(PET) or PET integrated with computed tomography (PET-CT)4. 
 
In the UK, when malignancy has spread to the axillary lymph nodes and is detected 
prior to surgery, axillary lymph node dissection (ALND) is normally indicated. Though 
more recently, there has been a shift in surgical opinion towards the potential for 
axillary conservation. Without definitive clinical or radiological evidence of malignancy 
in the axillary nodes, sentinel lymph node biopsy (SLNB) is usually undertaken (often 
with blue dye injection as an adjunct) to stage the axillary disease at the time of 
breast surgery for the breast malignancy. SLNB involves injecting the 
radiopharmaceutical technetium 99m-labeled albumin colloid via periareolar injection 
into the breast preoperatively. The most radioactive node in the axilla (the sentinel 
node) is identified intraoperatively by the surgeon, and is removed and sent for 
histopathological assessment. ALND involves the removal of all visible nodal tissue 
in the axilla. The operation carries considerable risk of long-term morbidity; 
lymphoedema is the most debilitating of these.  
 
Currently 25% of patients undergoing SLNB have histologically confirmed lymph 
node involvement and subsequently require ALND5; further surgery increases the 
risk of complications and morbidity.  
 
The accuracy of pre-operative staging with ultrasound is dependent on a number of 
factors including both the operator and test performance. A small retrospective case 
series comparing ultrasound with core needle biopsy, found a negative predictive 
value of 89%. 6Another small retrospective study of ultrasound guided final needle 
aspiration (FNA), found a positive predictive value of 100% and a negative predictive 
value of 79%.7 A prospective case series evaluated 102 patients with axillary 
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ultrasound and subsequent core biopsy; the negative predictive value was found to 
be 73%. 8 
 
A meta-analysis of data from 21 studies (4313 subjects) reported the median 
ultrasound sensitivity of 61.4%, with a specificity of 82% in detection of axillary nodal 
metastases. A subset of 1733 subjects from the meta-analysis was selected for 
ultrasound normal biopsy based on the ultrasound pictures. The median ultrasound 
sensitivity for the nodal biopsy was 79.4% and the median ultrasound node specificity 
was 100%. This meta-analysis indicates that the sensitivity of ultrasound alone as a 
staging technique is modest and cannot be reliably used to reassure patients 
regarding the absence of axillary nodal metastases. There is clear clinical difficulty in 
a test resulting in a false negative result of axillary node involvement, in which nodal 
disease is present but not detectable by conventional ultrasound techniques 
preoperatively.9    
 
Multidetector CT is an imaging technique that is rapidly performed and well tolerated 
by patients, but is not widely used within this area of clinical practice. Several studies 
have retrospectively evaluated CT assessment of axillary lymph nodes in patients 
with breast cancer 10-11 .  One prospective trial recruited 107 Japanese women with 
breast cancer to have axillary CT scans. Based on size criteria, CT demonstrated a 
sensitivity of 76% and a positive predictive value of 95% in predicting lymph 
nodemetastasis11  
  
Robust evidence is needed to understand the potential value of CT scans to improve 
pre-operative axillary staging in patients with newly diagnosed breast cancer. 
Consequently a trial was designed to evaluate the utility of multidetector computed 
tomography in this patient group. 
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Methods 
 
Study Design 
 
A multicentre randomised controlled trial using a PROBE (prospective randomised 
open, blinded end-point) design compared usual diagnostic care with CT-enhanced 
diagnostic care in patients presenting with primary breast cancer and in whom 
axillary surgery was planned. 
 
The trial was conducted at two large teaching hospitals in the North East of England, 
United Kingdom. Ethical approval for the protocol and all supporting documents 
including the participant information sheet and consent form was obtained prior to the 
study starting from Newcastle and North Tyneside 1 Research Ethics Committee, an 
independent ethics committee of the NHS National Research Ethics Service.  
 
Patients 
 
The trial recruited adults, female and male, with histopathologically confirmed, newly 
diagnosed breast cancer, in whom axillary surgery was planned. Patients had 
undergone ultrasound or mammography prior to entry into the trial, and were able to 
provide written informed consent. 
 
Patients were excluded if they were medically unstable, had a known allergy to 
iodinated contrast media, had severe allergic diasthesis, or required renal dialysis. 
Patients who had already received radiotherapy or surgery to the ipsilateral axilla, 
were receiving ongoing chemotherapy for a malignancy other than their current 
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breast cancer, required neoadjuvant chemotherapy for their current cancer, were 
pregnant, or had previously participated in the trial, were also excluded.  
 
All patients provided verbal consent over the phone at trial entry, and written consent 
at their next hospital visit. The process of consent to the trial was approved by the 
ethics committee.  
 
Randomisation and masking 
 
Patients were randomised in a ratio of 1:1 to receive usual diagnostic care or usual 
diagnostic care plus a CT of their axilla. Randomisation was stratified by operating 
surgeon and according to three age groups; patients aged 46 or below, patients aged 
47-69, and patients aged 70 or older at the time of presentation. Patients were 
randomised using a block size of 4; the clinical team were not informed of the block 
size used.  
 
Randomisation tables were generated by a statistician at Durham Clinical Trials Unit; 
password-protected, web-based access enabled clinical teams at the participating 
centres to randomise patients. On the basis of the stratification variables entered, the 
next available randomisation allocation was assigned and sent by email to the clinical 
team, as well as being displayed on the system. The randomisation tables were held 
centrally by Durham Clinical Trials Unit; users accessing the system were only shown 
the allocation for the patient being randomised, ensuring concealment of allocation. 
The nature of the trial intervention meant that clinical research teams and patients 
knew the allocation. The trial statistician was only given access to assigned groups 
once the database was locked for final analysis.  
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Trial procedures 
 
Patients in both arms of the trial had already undergone a routine axillary ultrasound 
examination with or without core biopsy at the time of their initial assessments and 
prior to trial entry. Following consent, patients in the usual care arm progressed 
directly to axillary and breast surgery as planned. Patients randomised to receive an 
axillary CT scan received this prior to their first planned operation for their breast 
cancer. Surgery was not delayed by taking part in the trial.  
 
All axillary imaging was performed on a helical multidetector CT scanner of at least 
64 slice imaging capacity from one of the following manufacturers: Siemens, General 
Electric (GE), Phillips, or Toshiba.  
 
Patients receiving an axillary CT scan had an intravenous cannula placed in their 
contralateral arm or hand from the side of the known breast cancer. The patient’s 
arms were positioned above their head. Non-ionic contrast medium (Niopam 300 or 
equivalent) was injected at a volume of 100 ml, at a rate of 3 ml per second. Imaging 
was performed after a delay of 40 seconds from the start of the injection. The 
radiographer set the scan range from the top of the chest to the bottom of the 
scapula using the scanning parameters as detailed in table 1.  
 
The field of view (FOV) was collimated from the skin surface to the lateral border of 
the vertebrae (on the affected side), to ensure imaging was confined to the axilla; it 
was not the purpose of the scan or the trial to detect occult metastatic disease.  
 
Axial images were reconstructed at 3 mm slice widths on soft tissue and lung 
algorithms in the coronal and sagittal planes. All three sets of images (axial, coronal, 
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and sagittal) were reported centrally at the lead centre by one of two consultant 
radiologists who were also part of the research team. Scans were reviewed and 
reported independently of other usual care imaging findings. Images were reviewed 
for: number of axillary lymph nodes present, size of the axillary lymph nodes, 
morphology (shape) of the nodes in terms of cortical irregularity and cortical 
thickness and enhanced pattern. The following criteria were included where relevant 
on the CT reports: multiple nodes greater than 5mm; irregular, non-ovoid nodes (<2:1 
long to short axis in diameter); loss of normal fatty hilum; cortical thickness greater 
than 3mm; enhancement of more than 20 Hounsfield units compared to a node with 
normal appearance.  
 
Axillary lymph nodes with four or more criteria were considered highly suspicious. 
Axillary lymph nodes with 2-3 criteria were considered equivocal. Axillary lymph 
nodes with one or fewer criteria were considered benign. 
  
 
 
The report of the findings of the CT scan was used to inform the multi-disciplinary 
team (MDT) decision-making process. Together with the results of axillary 
ultrasound, the CT scan results were discussed at the Breast MDT and the 
appropriate axillary surgery (either SLNB or ALND) determined. Where time did not 
allow, the results were discussed directly with the operating surgeon and changes to 
the planned axillary surgery were made as appropriate.   
    
Following surgery, the CT scan results were correlated with histopathological results 
obtained during axillary surgery (the reference standard) to determine the sensitivity 
and specificity of the CT examination. Histopathological determination was 
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conducted by a pathologist blinded to CT scan findings. Thus the performance of 
ultrasound (+/- core biopsy) and CT alone and in combination were estimated.  
 
Patients were followed for up to four weeks following their final episode of axillary 
surgery. Following histopathological confirmation that no further axillary surgery was 
required, patients were asked to complete a patient experience questionnaire, 
marking their completion in the study. Adverse events were recorded for both groups 
to the point of questionnaire completion.   
 
Outcomes 
The primary outcome was the change in the rate of re-operation on the axilla, 
comparing usual diagnostic care and usual diagnostic care plus CT of the axilla. Re-
operation occurred when patients who had been determined suitable for sentinel 
lymph node biopsy as their first axillary operation, had histopathologically confirmed 
disease in the excised axillary lymph node and thus required further surgery in the 
form of axillary lymph node dissection.  
 
Secondary outcomes were:  
• patient satisfaction determined using a patient satisfaction questionnaire 
completed over the phone by patients at the end of the study;  
• the test performance of routine perioperative imaging with and without multi-
detector CT in correctly selecting patients for surgery against 
histopathological reference standard findings;   
• the sensitivity, specificity, and positive and negative predictive values of 
ultrasound of the axilla, ultrasound with needle sampling and multidetector 
CT; 
• economic analysis; and  
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• rates of common post-surgical complications. 
 
Statistical Analysis 
Assuming alpha of 5% and power of 90%, a sample of 143 patients per group (286 in 
total) was required to detect an absolute difference in reoperation rates of 15% (25% 
in the control group and 10% in the intervention group). The study recruited 297 
patients between January 2011 and February 2014. 
 
The need for re-operation of the axilla was estimated as the difference in proportions 
between the two groups using Fisher’s exact test. Primary inference was based on 
the primary endpoint analysis of the intention-to-treat (ITT) population, with statistical 
significance assessed at the 5% level (2-sided). Logistic regression adjusted for 
stratifying factors (age and surgeon) provided secondary (supportive) analysis of the 
primary endpoint. Logistic regression findings were presented exponentiated as odds 
ratios (OR). 
 
Secondary measures involving categorical variables were estimated using Fisher’s 
exact test, with approximate (Miettinen) confidence intervals for reported proportions; 
continuous measures were evaluated using Students t-test, or non-parametric tests 
when required. Correlations between tests were estimated using the Spearman’s 
rank test.  
 
Adverse events were summarised and tabulated. Rates of adverse events were 
compared using negative binomial regression, with findings presented exponentiated 
as the incident rate ratio (IRR).  
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A cost analysis of the hospital care provided to intervention and control groups was 
conducted, including procedural data, from an NHS perspective and using bootstrap 
methods. Costs of procedures were obtained from national data. A cost-
consequences analysis was planned, setting incremental costs against reoperation 
rates, complications and levels of patient satisfaction.  
 
The trial was overseen by an independent data monitoring committee (IDMC) who 
met every four months for the duration of the trial. The IDMC adhered to a trial 
specific DAMOCLES charter.  
 
The trial was registered with the International Standard Randomised Controlled Trial 
Number database (ISRCTN03659464). 
 
 
Role of funding source 
This paper presents the findings of independent research commissioned by the 
National Institute for Health Research under its Research for Patient Benefit (RfPB) 
Programme (Grant Reference Number PB-PG-0609-18085). The views expressed 
are those of the authors, and not necessarily those of the NHS, the National Institute 
for Health Research or the Department of Health.  
 
Results 
The study recruited 297 patients from January 2011 to February 2014, receiving care 
within two NHS Hospital Trusts in the North-East of England. The recruitment rate 
was 69% of eligible patients approached. After recruitment, 5 patients were 
withdrawn and 1 died before surgery leaving 291 patients with outcome data and 
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contributing to analyses (see Figure 1). Patients received CT-enhanced care (CT) or 
usual care (UC).  
 
At baseline CT and UC groups were similar in demographic, disease and comorbidity 
measures (Table 2). Baseline characteristics were well balanced across both groups. 
 
At the first axillary operative procedure, the proportion of patients receiving ALND 
was similar (CT vs UC: 20.8% vs. 13.6%; CT-UC: 7.2%, 95%CI: = -1.5% to 16.0%, 
c2[1]: p=0.12) (Table 3).  The proportion of patients undergoing a second operation 
(the trial primary endpoint) was similar (CT vs UC: 19.4% vs. 19.7%; CT-UC: -0.3%, 
95%CI: = -9.5% to 8.9%, c2 [1]: p=1.00).  CT-enhanced pre-operative assessment 
had no statistically significant impact on the use of more invasive ALND as a first 
procedure and did not reduce the need for second surgery. 
 
Analysis of the primary endpoint within a general linear model (adjusted for stratifying 
variables within the randomisation) similarly found no difference between groups: 
adjusted OR: 1.00, 95%CI: 0.56 to 1.82, p=0.99). Other measures of surgery and 
disease for first and second surgical procedures were similar for both groups (Table 
3). There was no significant difference in cost between groups: CT-UC: £98, 95%CI: 
-£69 to £250, p=0.25, the non-significant increase being mainly accounted for by the 
cost of the CT scan (£86). 
 
Axillary ultrasound and CT findings were compared in those patients receiving CT. 
The correlation between the size of the largest node using the two methods was 0.52 
(p<0.01) and number of nodes detected was 0.38 (p<0.01). Similarly, levels of 
abnormality were significantly correlated: 0.524 (p<0.01) although discrepancies 
could account for the marginally higher initial CT group surgery rate if either test 
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being abnormal led to choosing more radical surgery (Table 4). It was not possible to 
compare the test accuracy of CT and ultrasound against the post-surgery 
histopathology indication for surgery. Although ‘false negatives’ were known (those in 
whom histopathology after first surgery identifies the need for a second radical 
operation), false positives were not known (those in whom histopathology does not 
confirm the selection of initial radical surgery).  
 
Patients completed a questionnaire following final surgery, which assessed their 
experience (Table 5). The level of distress from procedures and surgery was similar 
between groups, and levels of distress from CT were similar to those reported for 
mammography. 
 
Four adverse events (AEs) were reported related to receiving a CT scan: 1 report 
each of polyuria (mild), pruritus (moderate), pyrexia (mild) and nausea (mild). No 
serious AEs were reported related to receiving CT. Reported AEs due to first and 
second surgery were similar between groups (Table 6). The total number of reported 
AEs per patient was CT: 3.4 and UC: 3.2; IRR: 1.08, 95%CI: -0.83 to 1.40, p=0.55. 
The total number of reported AEs rated as severe per patient was CT: 0.15 and UC: 
0.06; IRR: 2.46, 95%CI: 1.10 to 5.52, p=0.03. 
 
Discussion: 
 
Identifying the presence of axillary lymph node metastasis in patients presenting with 
breast cancer is crucial in the decision-making process for determining the optimum 
treatment for the patient. Sentinel lymph node biopsy is the definitive method used to 
exclude axillary metastases, but this is an invasive surgical staging technique.  
Patients with SLNB results indicating axillary lymph node metastasis generally 
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undergo axillary lymph node dissection. In our trial, the addition of multidetector CT 
(with equipment of at least 64 slice capacity) to the patient pathway did not diminish 
the need for additional surgery, nor improve surgical outcomes or patient experience. 
It should be noted that a higher percentage of patients in the CT arm of the study did 
have ALND as a first procedure, 20.8% compared with 13.6% in the usual care group 
which suggests information from the CT scan about the nodal status is influencing 
the choice of initial surgery as in all other respects, the two control and study group 
were matched. 
 
Our study is however unique in that a diagnostic test was evaluated in a randomised 
fashion with a robust clinical outcome as the primary end point. Although there are 
numerous retrospective reviews and prospective studies evaluating test accuracy, 
this is, to the authors’ knowledge, the only study to evaluate the clinical utility of 
multidetector CT in a practise setting with the purpose of informing decisions about 
its adoption as a diagnostic intervention.  
 
The trial achieved an excellent recruitment rate (69%) of eligible patients who despite 
going through an extremely difficult life experience in their being diagnosed with 
cancer, were keen and motivated to take part in this trial. For the trial team, the 
logistical challenge of organising an additional CT scan, reporting the scan results, 
incorporating these into the clinical care pathway and MDT discussion where 
possible was challenging. In the context of this clinical pathway in which time is 
necessarily limited (the length of time from diagnosis to first operation for each 
patient was in the order of two weeks), this achievement should not be under-
estimated.  
 
It is now becoming clear from clinical studies such as the ACOSOG Z0011 research 
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study that a selected group of SLNB positive patients may be able to avoid ALND.  
In a retrospective study of practice in the USA, from information contained on the 
National Cancer Data Base, Bilimoria reported on 97314 patients; 23% of patients 
with SLNB macro metastases and 36% of patients with SNB micrometatases did not 
have ALND, yet for both groups with small volume nodal disease (pN1 and pN1m1) 
the axillary local recurrence rate and five year survival were the same as the group 
who had undergone the ALND.12 A number of other smaller retrospective studies 
have demonstrated low rates of axillary recurrence (0-2% in 28-82 months follow up) 
of patients who have had SLNB but have not gone on to have a ALND. The most 
robust evidence comes from the Z0011 trial, a prospective RCT in which 813 patients 
with SLNB results indicating axillary lymph node metastasis were randomised to 
ALND versus no further surgery. Additional positive nodes were found in 27% of 
patients who had ALND, but at six years follow up there were no significant 
difference between the ALND and no ALND arms in local, regional or overall loco-
regional recurrences, or in disease free survival.13 In the UK, the HTA has funded the 
POSNOC study14, a multicentre randomised controlled trial, addressing the same 
topic, although given the prolonged length of follow-up needed to accurately assess 
local recurrence in particular, it may be seven to eight years before the results of this 
trial are known. 
 
As there is a trend generally toward more conservation and less radical surgery in 
the axilla, many would argue the pre-operative staging of the axilla is becoming of 
greater importance. While ultrasound with needle biopsy technique remains standard 
practice internationally, it should be remembered that this diagnostic technique has 
not been studied in the context of a rigorous RCT.  
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It is likely that clinical questions about surgery involving the axilla will not be restricted 
by a binary solution of a positive/negative result, but rather will involve an 
assessment of the overall burden of disease, as it may well be that low volume 
axillary disease, found at SLNB, is better managed conservatively. Multidetector CT 
as an imaging tool provides standardised images in multiple planes, and gives an 
excellent overview of the anatomy of the axilla, the number of nodes present and the 
proximity of the nodal disease to structures such as the axillary vein. As has been 
demonstrated in our study, a simple but clear CT protocol can been supplied to 
experienced radiographers in two separate hospital sites with different CT 
equipment, and high quality and comparable images consistently achieved. The 
intra-operator variability associated with ultrasound and variability of ultrasound 
equipment performance is therefore avoided.  
 
Multidetector CT may have a role in the future in evaluating disease burden prior to 
axillary conservation and in imaging follow up of the “conserved” axilla. Further 
research using the latest generation of CT scanning equipment is needed to evaluate 
the clinical utility of CT in this different context and in the new world order of less 
radical surgery to the axilla. 
 
Conclusion: 
 
In conclusion, in this trial 20% of patients receiving usual care or usual care plus CT 
needed a second procedure; this is lower than the historical rate of 25%. The 
addition of multidetector computed tomography (CT) to the diagnostic assessment of 
patients with newly diagnosed breast cancer did not support the hypothesis that the 
reoperation rate of axillary surgery could be reduced to 15%. 
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New diagnostic imaging technologies are regularly introduced NHS centres. It is 
important these are rigorously evaluated before becoming routine care.  In patients 
with newly diagnosed breast cancer, the addition of an axillary CT scan was not 
found to reduce the need for further axillary operations, or to improve surgical 
outcomes or patient experience 
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Table 1: Summary of CT Scanning Parameters 
 
CT Operating mode: Scout View Anterioposterior and lateral; 
participant supine. Tube above and to 
the side of the patient.  
Helical Acquisition:  
Positioning Supine, arms elevated above the 
head 
Inspiration Suspended maximal 
Voltage (kV) 120 
Tube current-time product (mAs) Dose Modulated 
Detector collimation 1.0 
Scanning time < 25 seconds (beginning 40 seconds 
post contrast injection) 
Image reconstruction parameters:  
Nominal reconstructed slice width 
(mm) 
3.0 
Reconstruction interval (mm) 3.0 
Reconstruction algorithm Soft tissue and Lung 
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Table 2: Baseline Characteristics 
 
  Usual Care, UC (n=149) CT (n=148) 
Age, y 57 (48-68) 58 (48-69) 
BMI, kg/m2 27 (23-33) 27 (25-31) 
Gender     
Female 147 (99%) 147 (99.0%) 
Male 2 (1%) 1 (1.0%) 
Ethnicity     
White - British 149 (100.0%) 144 (97%) 
White - Other 0 (0.0%) 2 (1%) 
Asian - Indian 0 (0.0%) 1 (1%) 
Mixed - White and Black 0 (0.0%) 1 (1%) 
Other breast previously treated 7 (5%) 1 (1%) 
Breast with current cancer     
Right 69 (46%) 73 (49%) 
Left 80 (54%) 75 (51%) 
Mammographic grading      
Negative 6 (4%) 9 (6%) 
Benign 7 (5%) 10 (7%) 
Probably benign 41 (29%) 32 (23%) 
Suspicious abnormality 33 (23%) 35 (25%) 
Highly suggestive of malignancy 55 (40%) 54 (39%) 
Mammographic findings      
Stellate mass 41 (29%) 41 (31%) 
Asymmetric density 10 (7%) 15 (11%) 
Microcalcification 7 (5%) 9 (7%) 
Parenchymal deformity 1 (1%) 3 (2%) 
Multiple 19 (14%) 14 (11%) 
Other 63 (45%) 51 (38%) 
Grading of breast ultrasound      
Negative 0 (0%) 1 (1%) 
Benign 5 (3%) 4 (3%) 
Probably benign 24 (16%) 18 (12%) 
Suspicious abnormality 35 (24%) 34 (23%) 
Highly suggestive of malignancy 82 (56%) 91 (62%) 
Findings of breast ultrasound (BUS)     
Mass 101 (70%) 108 (75%) 
Microcalcification 3 (2%) 2 (1%) 
Multiple 10 (7%) 9 (6%) 
Other 31 (21%) 25 (17%) 
Diagnostic tests (BUS)     
Core biopsy (CB) 114 (77%) 117 (79%) 
Excision biopsy 5 (3%) 4 (3%) 
Fine needle aspiration cytology (FNA) 3 (2%) 0 (0%) 
FNA &CB 26 (18%) 27 (18%) 
Axillary ultrasound (AUS)     
Yes 146 (98%) 147 (100%) 
No 3 (2%) 0 (0%) 
Impression (AUS)     
Normal 113 (77%) 102 (69%) 
Equivocal 15 (10%) 15 (10%) 
Abnormal 18 (12%) 31 (21%) 
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Table 2: Baseline Characteristics (continued) 
 
  UC (n=149) CT (n=148) 
Number of nodes (AUS)     
0 67 (57%) 65 (54%) 
1 19 (16%) 24 (20%) 
2 26 (22%) 25 (21%) 
3+ 6 (5%) 7 (6%) 
Size of largest node, mm (AUS)      
0 mm 67 (55%) 65 (53%) 
1-5 mm 21 (17%) 19 (15%) 
6-10 mm 23 (19%) 25 (20%) 
10-15 mm 5 (4%) 9 (7%) 
>15 mm 5 (4%) 5 (4%) 
AUS guided biopsy 33 (22%) 45 (30%) 
Type of biopsy of axillary node     
Axillary core biopsy 19 (58%) 30 (67%) 
Axillary fine needle aspiration (FNA) 12 (36%) 10 (23%) 
Both 2 (6%) 5 (12%) 
Treatment before first surgery     
None 124 (83%) 122 (82%) 
Chemotherapy 0 (0%) 1 (1%) 
Hormonal therapy 23 (15%) 25 (17%) 
Diagnosis to randomisation, days 12 (8-14) 12 (8-13) 
Randomisation to surgery, days 20 (7-21) 18 (7-20) 
Data are number of patients (%) or median (IQR). 
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Table 3: Surgical Findings 
 
 UC CT p 
First axillary surgery    0.12 
SLNB 127 (86%) 114 (79%)  
ALND 20 (14%) 30 (21%)  
Number of axillary lymph nodes excised 4.1 ±4.7 5.5 ±6.5 0.03 
Nodes excised involved with cancer 1.0 ±2.3 1.7 ±4.0 0.09 
Second operation on the axilla required   1.00 
Yes 29 (20%) 28 (19%)  
No 118 (80%) 116 (81%)  
Axillary radiotherapy required   0.44 
Yes 10 (9%) 6 (5%)  
No 107 (92%) 109 (95%)  
ASA     0.47 
1 36 (26%) 44 (33%)  
2 83 (60%) 72 (53%)  
3 19 (14%) 19 (14%)  
4 1 (1%) 0 (0%)  
Grade of breast cancer    0.23 
In situ only 1 (1%) 3 (2%)  
Low grade 29 (20%) 17 (12%)  
Intermediate grade 56 (38%) 56 (39%)  
High grade 61 (42%) 68 (47%)  
Type of cancer    0.38 
Mixed 13 (9%) 11 (8%)  
Invasive Ductal Carcinoma 114 (78%) 104 (72%)  
Invasive Lobular Carcinoma 14 (10%) 20 (14%)  
Ductal Carcinoma in situ 1 (1%) 5 (4%)  
Lobular Carcinoma in situ 1 (1%) 0 (0%)  
Other 4 (3%) 4 (3%)  
Size of breast cancer, mm 25.5 ±18.4 26.6 ±16.2 0.57 
Length of operation, min  79.5 ±31.9 83.7 ±53.2 0.44 
Length of stay, d 0.9 ±1.2 1.1 ±1.5 0.27 
Second axillary surgery    1.00 
No  second surgery 118 (80%) 116 (81%)  
ALND 29 (20%) 28 (19%)  
Number of axillary lymph nodes excised   15.1 ±6.3 14.4 ±4.8 0.63 
Nodes excised involved with tumour 1.3 ±2.4 2.5 ±4.1 0.17 
Axillary radiotherapy required   0.61 
No 28 (97%) 26 (93%)  
Yes 1 (3%) 2 (7%)  
ASA     0.75 
1 6 (21%) 7 (26%)  
2 19 (68%) 19 (70%)  
3 3 (11%) 1 (4%)  
Type of cancer    0.95 
Mixed 2 (13%) 2 (14%)  
Invasive Ductal Carcinoma 5 (31%) 3 (21%)  
Invasive Lobular Carcinoma 2 (13%) 2 (14%)  
Length of operation (mins)   80.4 ±33.3 85.0 ±38.6 0.62 
Length of stay (days)  1.0 ±1.4 1.5 ±1.3 0.17 
Cost, £ 1257 ±735 1355 ±689 0.25 
Number of patients (%) or mean ±SD; probabilities by exact tests on counts; bootstrapping for continuous data. 
  
Page 25 of 30 
 
Table 4: Axillary ultrasound and CT findings of abnormality 
 
   
  Ultrasound  
  Normal Equivocal Abnormal Total 
CT 
Normal 85 9 4 98 
Equivocal 12 3 3 18 
Abnormal 3 2 23 28 
 Total 100 14 30 144 
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Table 5: Patient Experience Questionnaire 
 
 UC CT p 
Distress from tests 
Ultrasound     0.29 
No 121 98% 118 97%  
Yes 1 1% 4 3%  
Unclear 0 0% 0 0%  
NA 1 1% 0 0%  
Mammography     0.58 
No 115 94% 110 90%  
Yes 6 5% 8 7%  
Unclear 0 0% 0 0%  
NA 2 2% 4 3%  
FNA and/or biopsy     0.15 
No 26 87% 27 69%  
Yes 4 13% 12 31%  
Unclear 0 0% 0 0%  
NA 0 0% 0 0%  
CT Scanning      
No   110 90%  
Yes   9 7%  
Unclear   0 0%  
NA   3 3%  
Other procedure(s)     0.88 
No 20 16% 21 17%  
Yes 4 3% 2 2%  
Unclear 1 1% 2 2%  
NA 98 80% 97 80%  
Distress from surgery      
First surgery     0.71 
Very distressing 2 2% 6 5%  
- 3 3% 2 2%  
- 8 7% 7 6%  
- 5 4% 6 5%  
Not at all 103 84% 101 83%  
Unclear 1 1% 0 0%  
Second surgery     0.28 
Very distressing 1 2% 4 10%  
- 2 5% 0 0%  
- 5 12% 2 5%  
- 4 10% 6 15%  
Not at all 29 71% 27 69%  
Unclear 0 0% 0 0%  
Overall satisfaction with care   0.68 
Very satisfied 104 85% 107 88%  
- 14 11% 8 7%  
- 2 2% 4 3%  
- 2 2% 2 2%  
Not at all 1 1% 1 1%  
Unclear 0 0% 0 0%   
Data are number of patients (%); probabilities by exact tests on counts. 
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Table 6: Adverse events during surgery 
 
 UC CT p 
First Surgery (treated arm)      
Wound haematoma 7 (5%) 9 (6%) 0.62 
Wound infection 14 (10%) 10 (7%) 0.52 
Wound redness 15 (10%) 19 (13%) 0.47 
Discharge from wound 13 (9%) 17 (12%) 0.45 
Serous collections in the axilla 65 (45%) 77 (54%) 0.16 
Sensory symptoms/tingling/numbness  48 (33%) 56 (39%) 0.33 
Shoulder stiffness or movement problems  11 (8%) 14 (10%) 0.54 
Pain requiring IV or IM analgesia 11 (8%) 8 (6%) 0.64 
Other adverse event 106 (73%) 107 (74%) 0.79 
Second Surgery (treated arm)      
Wound haematoma 0 (0%) 2 (7%) 0.49 
Wound infection 3 (10%) 1 (3%) 0.61 
Wound redness 1 (4%) 0 (0%) 0.49 
Discharge from wound 3 (11%) 2 (7%) 0.67 
Serous collections in the axilla 27 (93%) 28 (97%) 1.00 
Sensory symptoms/tingling/numbness  22 (76%) 20 (69%) 0.77 
Shoulder stiffness or movement problems  10 (35%) 2 (7%) 0.02 
Pain requiring IV or IM analgesia 0 (0%) 1 (3%) 1.00 
Other adverse event 22 (76%) 21 (72%) 1.00 
Data are number of patients (%); probabilities by exact tests on counts. 
 
 
 
 
  
Page 28 of 30 
 
 
Figure1: Consort flow diagram 
 
 
 
 
 
 
  
Assessed for Eligibility (n=433) 
Excluded (n=136) 
•  Declined to participate (n=136) 
Randomized (n=297) 
CT Scan Enhanced Care, CT (n=148) 
Withdrawn before surgery (n=4) 
Included in analyses (n=144) 
Usual Care, UC (n=149) 
Died (n=1) 
Withdrawn before surgery (n=1)  
Included in analyses (n=147) 
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